Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control
In parallel with their development of the first synthetic gene drives – which greatly increase the chance a specific gene will be passed on to all offspring – George Church, Ph.D., and Kevin Esvelt, Ph.D., helped pioneer proactive biosafety measures to ensure that gene drives are investigated effectively and safely in confined laboratory experiments. They envision that synthetic gene drives designed using an RNA-guided gene editing system known as CRISPR-Cas9 – which works like a pair of molecular scissors to precisely cut or edit DNA – could one day be used outside of the lab to prevent transmission of deadly insect and animal-borne diseases and eradicate invasive species that threaten the ecosystem and agriculture.
Now, in a new study published in Nature Biotechnology on November 16, a team led by Church and Esvelt at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) demonstrates effective safeguarding mechanisms for working with gene drives and unveils a first-of-its-kind method for reversing the changes they spread.
“Any claim of reversibility of modern technology requires strong evidence,” said Church, who is a Wyss Core Faculty member, the Robert Winthrop Professor of Genetics at HMS, and Professor of Health Sciences and Technology at Harvard and MIT. “This is a major step in that direction for the field of synthetic biology.”
Alongside researchers on the Wyss Institute’s Synthetic Biology platform, Church and Esvelt, who is a Wyss Technology Development Fellow, have led the gene drive research community in discussions about responsible laboratory conduct and proactive confinement guidelines for the safeguarding of gene drive research. Their latest study verifies the efficacy of safeguarding protocols developed by their team, such as increased and improved physical biocontainment barriers and the introduction of so-called “molecular confinement” mechanisms which use genetic engineering to block laboratory organisms from surviving and reproducing in the highly unlikely event they ever escaped into the ecosystem.
“The gene drive research community has been actively discussing what should be done to safeguard shared ecosystems, and now we have demonstrated that the proposed safeguards work extremely well and should therefore be used by every gene drive researcher in every relevant lab organism,” said Esvelt.
CRISPR gene drives work by using sequences of RNA to guide the gene-cutting Cas9 protein to a specific target gene for editing. The molecular confinement mechanisms developed by the team prevent gene drives from functioning in the wild by manipulating these biological components. By separating the guide RNA and the Cas9 protein so that they are not encoded together in the same organism, or by inserting an artificial sequence into the targeted gene, gene drives can only be activated in lab organisms and are therefore not able to function in the wild.
“Using yeast in the lab, we also showed that a trait imposed on a population using a gene drive could be reversed,” said the paper’s first co-first author James Dicarlo, a graduate research assistant at the Wyss Institute and HMS. The team notes that using this safeguard, essentially any population-level change mediated by a gene drive could be subsequently overwritten if the need ever arose. In such a case, the originally imposed trait would be reversed and the biological “machinery” of the CRISPR gene drive system – the guide RNAs and the Cas9 protein – would remain present, albeit rendered inactive, in the DNA of organisms.
The reversibility mechanism isn’t just a useful backup to have on hand in case a gene drive ever had an unexpected side-effect; the ability to impose or reverse gene drive effects could also one day prove useful for the management of disease transmitting organisms such as mosquitoes, invasive species, and crop-destroying insects.
Although more research needs to be done in the lab before gene drives will ever potentially be ready for use outside of confined laboratory experiments, researchers now have the tools to perform those experiments safely. And in the meantime, gene drives themselves are useful lab tools for perturbing the genomes of lab organisms and unlocking new insights into the complex interplay of genes.
The Latest on: Gene drives
via Google News
The Latest on: Gene drives
- Drive to Doak: FHSAA names Doak Campbell Stadium as site for 2020 football finalson November 27, 2020 at 9:43 am
The Drive to Doak is on. The Florida High School Athletic Association ... The Class 1A through 3A finals were originally set for Gene Cox Stadium, also in Tallahassee, but will now be played at the ...
- OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysicson November 24, 2020 at 5:00 am
PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral ...
- Breast Cancer Metastasis, and Chemo Resistance Gene Identified as Target for Nanoparticle-Based Therapyon November 23, 2020 at 4:00 am
Researchers say “kiss of death” approach selectively reduces the expression of TRIM37 in cancer cells and prevents the spread.
- Gene Frenette: For Jaguars' sake, NFL draft and free agency can't arrive fast enoughon November 22, 2020 at 9:33 pm
A 27-3 loss to the unbeaten Pittsburgh Steelers only magnified the Jaguars' season-long troubles. Hope may not arrive until NFL free agency and draft.
- Thanksgiving Travel 2020: Worst Times To Drive In Floridaon November 22, 2020 at 1:45 pm
The coronavirus pandemic is expected to affect FL travel this Thanksgiving, but planning ahead will help you avoid any delays or surprises.
- Europe Gene Editing Market Revenue to Surpass USD 2.6 Billion by 2026on November 20, 2020 at 10:02 am
According to this report, the Europe gene editing market was valued at USD 1 billion in 2019 and is further projected to record a valuation of USD 2.6 billion by 2026 while depicting a growth rate of ...
- Asia Pacific Gene Editing Market Size to Exceed USD 2.1 Billion by 2026on November 19, 2020 at 2:03 pm
The research document drafted on Asia Pacific Gene Editing Market provides an in-depth analysis on this industry with accurate details pertaining to its overall foothold in the global landscape and ...
- Could key gene system discovery be suffocating corals' last gasp?on November 18, 2020 at 1:25 pm
Climate change and localised pollution are exposing marine life worldwide to lower oxygen levels leaving fragile coral reef ecosystems especially vulnerable. A unique experiment has given scientists ...
- Boosting Capabilities in Gene and Cell Therapy Bioprocessingon November 17, 2020 at 11:00 am
There’s a gap around handling manufacturing data in cell and gene therapy manufacturing,” explains Kwok Pang, the company’s co-founder and COO. “So, what we’re doing is providing that missing piece of ...
- AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipelineon November 17, 2020 at 8:00 am
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an ...
via Bing News